Design to come?

WP_Post Object
(
    [ID] => 2327
    [post_author] => 3
    [post_date] => 2024-07-09 08:24:41
    [post_date_gmt] => 2024-07-09 13:24:41
    [post_content] => 
    [post_title] => Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-inc-announces-first-patient-dosed-in-its-global-randomized-phase-3-study-invincible-3-in-metastatic-soft-tissue-sarcoma
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2024-07-09 08:24:41
    [post_modified_gmt] => 2024-07-09 13:24:41
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=2327
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)